首页> 外文OA文献 >The BRG1 Chromatin Remodeler Protects Against Ovarian Cysts, Uterine Tumors, and Mammary Tumors in a Lineage-Specific Manner
【2h】

The BRG1 Chromatin Remodeler Protects Against Ovarian Cysts, Uterine Tumors, and Mammary Tumors in a Lineage-Specific Manner

机译:BRG1染色质重塑剂以特定于世袭的方式保护卵巢囊肿,子宫肿瘤和乳腺肿瘤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The BRG1 catalytic subunit of SWI/SNF-related complexes is required for mammalian development as exemplified by the early embryonic lethality of Brg1 null homozygous mice. BRG1 is also a tumor suppressor and, in mice, 10% of heterozygous (Brg1null/+) females develop mammary tumors. We now demonstrate that BRG1 mRNA and protein are expressed in both the luminal and basal cells of the mammary gland, raising the question of which lineage requires BRG1 to promote mammary homeostasis and prevent oncogenic transformation. To investigate this question, we utilized Wap-Cre to mutate both Brg1 floxed alleles in the luminal cells of the mammary epithelium of pregnant mice where WAP is exclusively expressed within the mammary gland. Interestingly, we found that Brg1Wap-Cre conditional homozygotes lactated normally and did not develop mammary tumors even when they were maintained on a Brm-deficient background. However, Brg1Wap-Cre mutants did develop ovarian cysts and uterine tumors. Analysis of these latter tissues showed that both, like the mammary gland, contain cells that normally express Brg1 and Wap. Thus, tumor formation in Brg1 mutant mice appears to be confined to particular cell types that require BRG1 and also express Wap. Our results now show that such cells exist both in the ovary and the uterus but not in either the luminal or the basal compartments of the mammary gland. Taken together, these findings indicate that SWI/SNF-related complexes are dispensable in the luminal cells of the mammary gland and therefore argue against the notion that SWI/SNF-related complexes are essential for cell survival. These findings also suggest that the tumor-suppressor activity of BRG1 is restricted to the basal cells of the mammary gland and demonstrate that this function extends to other female reproductive organs, consistent with recent observations of recurrent ARID1A/BAF250a mutations in human ovarian and endometrial tumors.
机译:SWI / SNF相关复合物的BRG1催化亚基是哺乳动物发育所必需的,例如Br​​g1空纯合小鼠的早期胚胎致死率。 BRG1还是一种肿瘤抑制物,在小鼠中,有10%的杂合子(Brg1null / +)雌性小鼠患乳腺肿瘤。现在,我们证明BRG1 mRNA和蛋白在乳腺的腔和基底细胞中均有表达,从而提出了哪个谱系需要BRG1促进乳腺稳态并防止致癌转化的问题。为了调查这个问题,我们利用Wap-Cre突变了妊娠小鼠乳腺上皮腔细胞中的两个Brg1固定等位基因,其中WAP仅在乳腺内表达。有趣的是,我们发现Brg1Wap-Cre条件纯合子正常泌乳,即使将其维持在缺乏Brm的背景下也不会发生乳腺肿瘤。但是,Brg1Wap-Cre突变体确实发生了卵巢囊肿和子宫肿瘤。对这些后一种组织的分析表明,这两种组织都像乳腺一样,都含有正常表达Brg1和Wap的细胞。因此,Brg1突变小鼠中的肿瘤形成似乎仅限于需要BRG1并表达Wap的特定细胞类型。我们的结果现在表明,这种细胞既存在于卵巢也存在于子宫,但不存在于乳腺的腔或基底腔。综上所述,这些发现表明,SWI / SNF相关的复合物在乳腺腔细胞中是可有可无的,因此与SWI / SNF相关的复合物对于细胞存活至关重要的观点背道而驰。这些发现还表明,BRG1的抑癌活性仅限于乳腺的基底细胞,并证明该功能扩展到其他女性生殖器官,这与最近在人卵巢和子宫内膜肿瘤中复发性ARID1A / BAF250a突变的观察结果一致。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号